Research group on Status Epilepticus and Acute Seizures : VHIR Annual Report 2020

Neurosciences

< Back

Overview

The Neuroscience area is consolidating its position as one of the largest clusters of research labs working on neurological diseases across Europe. At present, the area comprises 14 groups with more than one hundred fully dedicated researchers in close contact with top clinicians in the hospital. These research groups pursue a better and multifaceted understanding of the etiopathogenic mechanisms underlying a large variety of mostly adult but also pediatric neurological disorders including stroke, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, primary headaches, epilepsy, neuromuscular disorders, and also neurosurgical and psychiatric pathologies. The area also integrates groups involved in neuroimaging, analysis and interpretation of high-throughput data, and gene therapy strategies to target inflammatory and neurodegenerative neurological conditions.

Publications

316
total
1898
impact factor
6.01
average impact factor

Group Leader: Estevo Santamarina Pérez

During 2020, the Research Group on Status Epilepticus and Acute Seizures has identified new biomarkers that can help predict the development of epileptic seizures after an acute stroke event, a study that is part of a project of the Marató TV3 and which has led to high impact factor publications and a doctoral thesis (Laura Abraira). A FIS project has also been initiated to study new biomarkers to detect the presence of status epilepticus. In addition, Dr. Santamarina has co-led the consensus document on the management of emergent epileptic seizures, which was published in 2020. On the other hand, new associations have been established between changes in brain volume and cognitive status in patients with temporal epilepsy, leading to another doctoral thesis (Elena Fonseca). Also noteworthy is a recently published study on the effects of the COVID19 pandemic on patients with epilepsy, which has been widely reported in the media. In addition, a clinical trial has been initiated to evaluate the efficacy and safety of CVL-865 in patients with convulsive seizures.

VHIR Annual Report 2020